Medicines Patent Pool (MPP) Archives - Medical Design Sourcing

The Medicines Patent Pool (MPP) announced that it has signed agreements with 35 manufacturers to make an inexpensive version of Pfizer’s (NYSE: PFE) Paxlovid (nirmatrelvir/ritonavir) to be distributed in 95 low- and middle-income countries.

Vaccination rates in many developing countries lag far behind that of wealthier countries. In Nigeria, for instance, 9.1% of the population has received at least one dose, whereas 77% of those in the U.S. are partially or fully vaccinated.

The U.S. pays roughly $530 for a course of Paxlovid.

Pfizer has previously stressed its goal of providing equitable access to COVID-19 therapies worldwide. In November 2021, the company entered a deal with MPP to ensure the availability of Paxlovid to low- and middle-income countries.

“Nirmatrelvir is a new product and requires substantial manufacturing capabilities to produce, and we have been very impressed with the quality of manufacturing demonstrated by these companies,”…

Image courtesy of Merck & Co.

The Medicines Patent Pool (MPP) announced today that it signed agreements with 27 manufacturers to produce Merck’s COVID-19 pill.

MPP’s agreements with the generic manufacturing companies cover the manufacturing of the oral COVID-19 antiviral medication molnupiravir, with supply set for 105 low- and middle-income countries (LMICs). The agreements come as a result of the voluntary licensing agreement signed by MPP and MSD, a trade name of Merck, to facilitate the affordable global access of the antiviral drug that MSD is developing in partnership with Ridgeback Biotherapeutics.

Companies offered the sublicenses — which allow generic manufacturers to produce the raw ingredients for molnupiravir and/or the finished drug itself — successfully demonstrated their ability to meet MPP’s requirements related to production capacity, regulatory compliance and t…

Medicines Patent Pool (MPP)

Manufacturers ink deal to make generic version of Pfizer’s oral COVID-19 pill Paxlovid

Generic manufacturers to make cheaper version of Merck’s COVID-19 pill for developing countries